BlackRock Fund Advisors’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
VC
SMV
PA
RSCM
CAM
PC
BlackRock Fund Advisors's ACRS Position: Q4 2016 in Review
BlackRock Fund Advisors increased its Aclaris Therapeutics (ACRS) stake by 36% in Q4 2016, buying an estimated $2.44M and bringing the position to 362,192 shares worth $9.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2584.
BlackRock Fund Advisors first reported a position in ACRS in Q4 2015 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold ACRS as of Q4 2016.
- BlackRock Fund Advisors held 362,192 shares of Aclaris Therapeutics worth $9.83M as of Q4 2016.
- BlackRock Fund Advisors bought 95,640 Aclaris Therapeutics shares in Q4 2016, an estimated $2.44M.
- Aclaris Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2584 holding.
- BlackRock Fund Advisors first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 5 quarters since.
- 100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2016.
Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.